Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; OPN 6602 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Opna Bio

    • Most Recent Events

    • 11 Feb 2025 According to an Opna Bio media release, the company expects complete the single agent, dose-escalation phase of the trial in 2026.
    • 26 Aug 2024 According to an Opna Bio media release, the company expects to enroll up to 90 patients in the dose-escalation cohort, with an additional 40 patients in the dose-expansion cohort. The completion date is expected in the second half of 2026.
    • 26 Aug 2024 According to an Opna Bio media release, the first patient of this study has been dosed at The START Center for Cancer Research in Grand Rapids, Michigan with Dr. Andrew Sochacki, principal investigator, leading the study team.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top